 |
17 Diseases |  |
8 Trials |
|
8 Trials |  |
676 News |  |
| «12345678910 |
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects (clinicaltrials.gov) - Jun 23, 2016
P1, N=40, Active, not recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: Comparison of Two Dose Strengths of Selexipag in Healthy Adults (clinicaltrials.gov) - Jun 23, 2016
P1, N=20, Active, not recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: TRANSIT-1: Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 21, 2016
P3, N=30, Active, not recruiting, Sponsor: Actelion
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment open: A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects (clinicaltrials.gov) - Jun 10, 2016
P1, N=40, Recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
New P1 trial: Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects (clinicaltrials.gov) - Jun 9, 2016
P1, N=20, Not yet recruiting, Sponsor: Actelion
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
New P1 trial: A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects (clinicaltrials.gov) - May 12, 2016
P1, N=40, Not yet recruiting, Sponsor: Actelion
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial primary completion date: ACT-293987 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - May 3, 2016
P3, N=670, Active, not recruiting, Sponsor: Actelion
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Feb 2021
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
New P1 trial: Comparison of Two Dose Strengths of Selexipag in Healthy Adults (clinicaltrials.gov) - Apr 20, 2016
P1, N=20, Not yet recruiting, Sponsor: Actelion
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial primary completion date: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 1, 2016
P3, N=1156, Completed, Sponsor: Actelion
Trial primary completion date: Dec 2017 --> Feb 2021 Trial primary completion date: Sep 2014 --> Apr 2014
- || Enrollment closed, Trial primary completion date: PAH QuERI Ext: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=800, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Sep 2014 --> Apr 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2018
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment open: TRANSIT-1: Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 15, 2015
P3, N=30, Recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2018 Not yet recruiting --> Recruiting
- |||||||||| Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
New P3 trial, Combination therapy: TRITON: The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 23, 2015
P3, N=144, Not yet recruiting, Sponsor: Actelion
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
New P3 trial: TRANSIT-1: Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 15, 2015
P3, N=30, Not yet recruiting, Sponsor: Actelion
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial completion: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - May 22, 2015
P2, N=74, Completed, Sponsor: Actelion
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Feb 27, 2015
P2, N=74, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial completion: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Feb 27, 2015
P3, N=1156, Completed, Sponsor: Actelion
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment open: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Oct 31, 2014
P2, N=70, Recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
New P2 trial: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Oct 10, 2014
P2, N=70, Not yet recruiting, Sponsor: Actelion
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial primary completion date: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 28, 2014
P3, N=1156, Active, not recruiting, Sponsor: Actelion
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Sep 2014
- ||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed, Trial primary completion date: ACT-293987 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 28, 2014
P3, N=670, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Mar 2014 --> Sep 2014 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2017
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
New P1 trial: Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 ?g Selexipag Administered as Eight Tablets of 200 ?g or as Single Tablet of 1600 ?g (clinicaltrials.gov) - Aug 1, 2014
P1, N=80, Completed, Sponsor: Actelion
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
New P1 trial: Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects (clinicaltrials.gov) - Aug 1, 2014
P1, N=159, Completed, Sponsor: Actelion
- ||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - May 27, 2013
P3, N=1156, Active, not recruiting, Sponsor: Actelion
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2017 Recruiting --> Active, not recruiting